STORM Therapeutics raises €47.5 million Series C to harness the power of RNA modification to treat cancer

STORM Therapeutics (STORM), a Cambridge-based BioTech company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced that it has secured €47.5 million ($56 million) in Series C financing. The financing was secured from existing investors, M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, the